Collaborative projects

Fasilis: facility sharing in Life Science

April 2010. Spinnovation participates in the translational pilot project FASILIS that aims to give Small and Medium sized Enterprises (SMEs) in the human health sector, such as biotechnology, pharmaceuticals and medical technology, easy access to a wide range of public and private research facilities in six human health clusters.

PREDICCt : Prevention and Early Detection of Cardiovascular Complications in DM2

In november 2008, Spinnovation has entered into a 5-year research collaboration with members of the dutch Center for Translational Molecular Medicine (CTMM). The PREDICCt consortium will combine the latest insights into the causes of DM2 with innovative technologies to identify risk-indicators (biomarkers) for DM2 and DM2-related complications with the objective of:

• identifying people at risk of obesity and DM2
• identifying DM2 patients with an increased risk of cardiovascular complications
• gaining insight into strategies to diagnose diabetic vascular disease at an early stage

The project benefits from the support and partcipation of  industrial partners such as Schering-Plough/MSD, Danone Research, BG-medicine. (See press release).

Hyphen-ID : hyphenated analytical technologies for the identification of unknows

In january 2008, the companies Spinnovation Analytical BV, Schering-Plough / Merck Sharp and Dohme, Synthon BV, Bruker Biospin Gmbh and the Radboud University have entered into a 4-year research collaboration dedicated to the development of new analytical methodologies and tools for Impurity Profiling and Metabolite Identification. (See press release)